News
Helgi Kormaksson Joins CTS Executive Team SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / CTS is excited to announce that Helgi Kormaksson has joined the company as Chief Design Officer. Helgi ...
Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...
Medicinalgiganten Novo Nordisk afviser, at der er en sammenhæng mellem behandling med slankemidlet Wegovy og øjensygdommen ...
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...
Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...
USA's højesteret giver foreløbigt den såkaldte effektiviseringsenhed Department of Government Efficiency (DOGE) adgang til ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.
B.T. on MSN14h
Novo Nordisk åbner for ændringer: Klar til samarbejdeNovo Nordisk gør det klart, at medicinalgiganten vil samarbejde med Det Europæiske Lægemiddelagentur, når det gælder ...
Novo Nordisk afviser, at der er en årsagssammenhæng mellem behandling med Wegovy og øjensygdommen Naion. Det skriver medicinalvirksomheden i en kommentar til DR.
Zacks Investment Research on MSN19h
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...
Det har fredag presset prisen på Gubra-aktien i vejret til en kurs på cirka 468 kroner mod knap 395 kroner per aktie 2. juni.
Der har natten til lørdag været meldinger om et omfattende russisk luftangreb rettet mod Ukraines næststørste by, Kharkiv.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback